This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
DPP Audience & Provider Insights for the DPP Research and Marketing Plan: Phase 1 Research Findings
Frequently Asked Questions About the Dual Prevention Pill (DPP)
This factsheet provides answers to the most frequently asked questions about the Dual Prevention Pill (DPP), including what it is, who might use it, and how it can be rolled out.
Dual Prevention Pill: Market Preparation and Introduction Strategy
This strategy, updated in August 2023, is intended for donors, governments, implementing partners and civil society to inform priorities and planning for DPP rollout. The strategy describes activities required to build a cohesive body of evidence and recommends an approach to DPP introduction to focus efforts. Where possible, activities will be embedded into existing programs to consolidate and leverage resources.
HIV Prevention Choice Manifesto
The HIV Prevention Choice Manifesto emphasizes community-led leadership and the importance of choice in HIV prevention for African women and girls. The manifesto advocates for universal access to a broad range of biomedical tools for HIV prevention and underscores the transformative potential when African women and girls lead advocacy and response efforts in HIV healthcare.
More information and background on the manifesto is available on our blog.
Px Wire May 2023
Volume 13, Number 2
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of PxWire.
PEPFAR at 20: Keeping the promise
2023 is a big year for PEPFAR. Considered one of the greatest US foreign policy and global development achievements of the century, the program has saved upwards of 25 million lives since it launched in 2003. But PEPFAR is marking its 20th anniversary while fighting for its future.
Its authorization expires September 30. Until a couple of months ago, most expected smooth sailing in the US Congress for a five-year reauthorization of the program. PEPFAR has enjoyed deep and broad bipartisan support since its founding. Evangelical Christians, staunch conservatives, DC Democrats, progressive HIV activists, and public health leaders have championed PEPFAR, year in and year out. But a handful of Republicans, including past PEPFAR allies, are pulling reauthorization into high-stakes partisan politics.
In this episode, Px Pulse talks to some of the people who put PEPFAR dollars into action and to global health leaders who explain why PEPFAR’s approach has been so effective, and what’s at stake in this debate.
Tune in to hear:
- Ilda Kuleba from Mothers 2 Mothers talks about the impact of their work across 10 countries, training and employing HIV positive mothers as peer healthcare workers.
- Dr. James Mukabi of World Vision’s Kenya program talks about how this Christian relief organization has changed the lives of thousands of orphans and other populations who are vulnerable to HIV.
- Tom Hart, President of the One Campaign, which was founded by the rock star Bono, to be an early champion of PEPFAR and other poverty fighting efforts talks about PEPFAR’s accomplishments at the global level and what’s next as congress debates reauthorizing the program.
Links:
Advocacy Resources:
- Global AIDS Policy Partnership (GAPP)
- KFF’s page on PEPFAR
- PEPFAR at 20: John Meade, Senior Program Manager for Policy at AVAC
Media:
HIV Prevention Research & Development Investments 2021
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms and prevention of vertical transmission (PVT). More information at hivresourcetracking.org.
Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?
May 17, 2023
With several large HIV vaccine trials in the last few years finding no efficacy, the field is in transition. There are diverse ideas in vaccine research, but there’s no clear concept that’s ready to test in a late-phase trial or move towards product development currently. Researchers are back to testing new ideas in early phase research.
In this episode of our Px Pulse podcast, Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?, Dr. Katy Stephenson explores the implications of recent trial results, the big questions driving next generation vaccine development, and new strategies underway in early phase research. Katy is a doctor, a researcher, a professor of medicine at Harvard Medical School, affiliated with Beth Israel Deaconess Medical Center, and part of the Center for Virology and Vaccine Research.
Listen
Resources
HIV Vaccine Awareness Day (HVAD) 2023
In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.
Advancing HIV Cure to Africa: What is needed?
The HIV epidemic continues to have a tremendous impact on global health. While we have made enormous progress in making antiretroviral therapy available to many people living with HIV, we are still not capable of eliminating infection. Consequently, people with HIV must commit to expensive, lifelong therapies; continuous monitoring; and they face drug toxicities and chronic immune activation. There is thus an urgent need to develop safe, affordable, and globally accessible curative strategies. While HIV cure research slowly becomes more mainstream in high income countries, Africa runs the risk of being left behind.
During two exciting 60-minutes panel-discussions panelists discussed how researchers, communities and other stakeholders from high income countries could work equitably with low- and middle-income countries in the interests of an HIV cure for all. This webinar was one session of the NL4Cure Spring symposium in Rotterdam on May 25 and 26.
Panel discussion 1 – Scientific priorities for HIV cure in Africa
Facilitated by Cynthia Lungu, Erasmus University Medical Center.
Panelists included Professor Thumbi Ndung’u, Africa Health Research Institute Programme, Krista Dong, MD, of FRESH- Females Rising through Education, Professor Zaza Ndhlovu, Africa Health Research Institute, Catherine Slack, MA Clin Psych, PhD, HIV AIDS Vaccines Ethics Group
Panel discussion 2 – Advocacy and community involvement priorities for HIV cure in Africa
Facilitated by Jessica Salzwedel, AVAC.
Panelists included Philister Adhiambo, Kenya Medical Research Institute, Charles Brown, Preventive Care International, Mandisa Dukashe, Wits RHI, Elina Mwasinga, National Association for Young People Living with HIV
Aidsfonds: Soa Aids Nederland is a Dutch non-profit organization that also works internationally. Working with communities as equals is at the heart of all our work. We conduct research and ensure that HIV, AIDS and STIs remain high on the agenda worldwide. Together we are working to find a cure for HIV.
NL4Cure: Aidsfonds has initiated a unique partnership to bring together the best HIV researchers, people living with HIV, data experts, HIV clinicians and nurses. Through NL4Cure, we generate new insights that bring us one step closer to finding a cure.